PetCaseFinder

Peer-reviewed veterinary case report

Spindle cell mammary tumors in dogs - study of 67 cases

By Alonso-Diez, Ángela et al.·Published in Veterinary pathology·2019·1 Department Animal Medicine, Spain·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Canine Spindle Cell Mammary Tumor: A Retrospective Study of 67 Cases.

Species:
dog

Plain-English summary

A dog with a mammary tumor was diagnosed with a rare type called a spindle cell mammary tumor. Out of 67 cases studied, most were found to be malignant, but they generally had a low chance of spreading and a good survival rate. The tumors were often large and solitary, and the diagnosis could change significantly when more advanced testing was done. In fact, 75% of the malignant tumors had a different diagnosis after further examination. This highlights the importance of thorough testing for accurate diagnosis and treatment planning.

People also search for: dog mammary tumor treatment · spindle cell tumor in dogs · dog cancer survival rate · signs of dog breast cancer

Abstract

Canine spindle cell mammary tumor (CSCMT) is an infrequent canine mammary tumor (CMT) composed of spindle or fusiform cells, which represents a challenge for pathologists and clinicians. Mammary tumors submitted for histopathology from 1998 to 2013 and compatible with CSCMTs were retrospectively selected. The tumors were diagnosed based on the hematoxylin and eosin (HE)-stained section; malignant tumors were graded using a canine soft tissue sarcoma grading scheme and a canine mammary tumor grading scheme, and they were further assigned a diagnosis based on immunohistochemistry (IHC) for pancytokeratin, cytokeratin 14, p63, calponin, vimentin, Ki-67, CD31, desmin, myosin, smooth muscle actin, glial fibrillary acidic protein, and S-100. The origin of the tumors was assessed as mammary, skin, or unknown. The prevalence of CSCMT was 1% of all CMTs. CSCMTs included 3 benign tumors (1 angioma and 2 benign myoepitheliomas) and 67 malignant tumors that after IHC were diagnosed as malignant myoepithelioma (64%), carcinoma and malignant myoepithelioma (19%), hemangiosarcoma (8%), undifferentiated sarcoma (5%), peripheral nerve sheath tumor (3%), and fibrosarcoma (2%). The diagnosis based on the HE-stained section differed from the diagnosis after IHC in 75% of the malignant cases. The majority of malignant CSCMTs were solitary (57%) large tumors (6.42 ± 3.92 cm) with low metastatic potential and high survival rate (8% tumor-related mortality). Higher sarcoma grade was associated with older age (= .034) and greater tumor size (= .037). Malignant CSCMTs need to be evaluated by IHC to ensure the histotype and the relatively benign clinical behavior, despite their large size.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/30857503/